GlaxoSmithKline plc (LON:GSK) has analysts on the Bullish side this week.

October 13, 2017 - By test

 GlaxoSmithKline plc (LON:GSK) has analysts on the Bullish side this week.

GlaxoSmithKline plc (LON:GSK) Ratings Coverage

Among 28 analysts covering GlaxoSmithKline PLC (LON:GSK), 8 have Buy rating, 4 Sell and 16 Hold. Therefore 29% are positive. GlaxoSmithKline PLC had 391 analyst reports since July 28, 2015 according to SRatingsIntel. Bernstein maintained it with “Market Perform” rating and GBX 1401 target in Friday, October 16 report. The stock of GlaxoSmithKline plc (LON:GSK) earned “Hold” rating by Helvea on Tuesday, January 26. The firm has “Buy” rating by Citigroup given on Monday, April 25. BNP Paribas maintained the stock with “Neutral” rating in Monday, February 1 report. The rating was maintained by Liberum Capital with “Buy” on Thursday, February 9. JP Morgan maintained the stock with “Neutral” rating in Friday, August 12 report. The firm earned “Overweight” rating on Thursday, February 4 by Barclays Capital. Citigroup maintained it with “Neutral” rating and GBX 1550 target in Wednesday, September 9 report. UBS maintained GlaxoSmithKline plc (LON:GSK) rating on Tuesday, December 13. UBS has “Neutral” rating and GBX 1600 target. The firm has “Buy” rating given on Thursday, February 9 by HSBC. Below is a list of GlaxoSmithKline plc (LON:GSK) latest ratings and price target changes.

11/10/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 1610.00 New Target: GBX 1610.00 Maintain
04/10/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 1900.00 New Target: GBX 1760.00 Maintain
02/10/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 1570.00 New Target: GBX 1570.00 Maintain
21/09/2017 Broker: JP Morgan Rating: Neutral Maintain
20/09/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 1610.00 New Target: GBX 1610.00 Maintain
19/09/2017 Broker: Berenberg Rating: Buy Old Target: GBX 1835.00 New Target: GBX 1835.00 Maintain
18/09/2017 Broker: Jefferies Rating: Buy Old Target: GBX 1750.00 New Target: GBX 1675.00 Reiteration
19/09/2017 Broker: Bryan Garnier & Cie Rating: Neutral Old Target: GBX 1710.00 New Target: GBX 1710.00 Maintain
19/09/2017 Broker: Shore Capital Rating: Hold Maintain
14/09/2017 Broker: Shore Capital Rating: Hold Maintain

The stock decreased 0.66% or GBX 10.04 on October 13, reaching GBX 1517.46. About 5.53M shares traded. GlaxoSmithKline plc (LON:GSK) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

GlaxoSmithKline plc is a global healthcare company. The company has market cap of 74.64 billion GBP. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 38.47 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

More recent GlaxoSmithKline plc (LON:GSK) news were published by: Nasdaq.com which released: “Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?” on September 20, 2017. Also Streetinsider.com published the news titled: “Innoviva (INVA) & GlaxoSmithKline Plc (GSK) Granted Approval by FDA for Once …” on September 19, 2017. Bloomberg.com‘s news article titled: “Glaxo Finds a Rich Vein to Mine With Supercomputers” with publication date: October 13, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.